98%
921
2 minutes
20
Introduction: To evaluate the risk of venous thromboembolic events in patients operated with radical cystectomy or radical prostatectomy and pelvic lymph-node dissection.
Material And Methods: Patients operated with radical cystectomy for bladder cancer or with radical prostatectomy for prostate cancer from 1997 through 2016 were identified from Swedish nationwide registers. We estimated odds ratios of association between lymph-node dissection and pulmonary embolism and deep venous thrombosis (DVT) using logistic regression adjusted for the probability of having lymph-node dissection.
Results: In total, 6069 patients operated with radical cystectomy and 36 911 patients with radical prostatectomy were included. The risk of pulmonary embolism and DVT after radical cystectomy with lymph-node dissection was 1,89 % and 2,29 %, and without lymph-node dissection 1,99 % and 2,35 %, respectively. After radical prostatectomy and lymph-node dissection the risk for pulmonary embolism and DVT were 0,97 % and 1,36 %, and without lymph-node dissection 0,42 % and 0,49 %, respectively. Pelvic lymph-node dissection during a radical cystectomy was not associated with pulmonary embolism (OR 0,99; 95 % CI 0,65-1,51) or DVT (OR 0,99; 95 % CI 0,68-1,48), whereas lymph-node dissection during radical prostatectomy was associated with higher odds of both pulmonary embolism (OR 2,29; 95 % CI 1,67-3,09) and DVT (OR 2,95; 95 % CI 2,27-3,85).
Conclusion: Pelvic lymph-node dissection did not increase the risk of venous thromboembolism after a cystectomy, whereas we found an increased relative risk of venous thromboembolic events associated with radical prostatectomy with lymph-node dissection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejso.2025.110326 | DOI Listing |
Ann Gastroenterol Surg
September 2025
Department of Gastrointestinal Surgery, Graduate School of Medicine The University of Tokyo Tokyo Japan.
Background: This study aimed to investigate survival outcomes, the efficacy of lymph node (LN) dissection, and recurrence patterns in patients who underwent salvage surgery (SALV) for esophageal squamous cell carcinoma (ESCC) after definitive chemoradiotherapy (dCRT).
Methods: We retrospectively reviewed 69 patients with clinical stage I-IV thoracic ESCC who underwent SALV. Recurrence patterns and the distribution of LN metastases were analyzed according to the primary tumor location.
Ann Gastroenterol Surg
September 2025
Division of Molecular and Diagnostic Pathology, Graduate School of Medical and Dental Sciences Niigata University Niigata Japan.
Aims: To determine the optimal extent of lymph node dissection for non-metastatic colon cancer by tumor location based on the therapeutic value index (TVI) for each lymph node station.
Methods: Consecutive patients with surgical stage I-III colon or rectosigmoid cancer in the Japanese Society for Cancer of the Colon and Rectum database who underwent curative resection between January 2003 and December 2014 were analyzed. The TVI was defined as the incidence of lymph node metastasis multiplied by 5-year overall survival and calculated for each nodal station stratified by tumor location.
Prostate Cancer Prostatic Dis
September 2025
Department of Urology, Department of Health Science, University of Milan, ASST Santi Paolo e Carlo, Milan, Italy.
Introduction: The introduction of novel robotic platforms has expanded surgical options for robot-assisted radical prostatectomy (RARP). However, comparative outcomes with da Vinci multiport (MP) system remain unclear. This systematic review and network meta-analysis aimed to compare perioperative, early oncological, and functional outcomes of RARP performed with novel robotic platforms versus the da Vinci MP system.
View Article and Find Full Text PDFDis Esophagus
October 2025
Department of Surgery, Keio University School of Medicine, Tokyo, Japan.
Clinical practice guidelines for esophagogastric junction cancer (EGJ GLs) were published in 2023. In order to evaluate how EGJ GLs have been adopted into clinical practice worldwide and to identify any outstanding clinical questions to be addressed in the next edition, this survey was conducted. An electronic questionnaire was developed.
View Article and Find Full Text PDFJ Vis Exp
August 2025
Department of Breast and Thyroid Surgery, Daping Hospital, Army Medical University; Key Laboratory of Chongqing Health Commission for Minimally Invasive and Precise Diagnosis and Treatment of Breast Cancer;
The integration of robotic platforms in breast oncology has witnessed substantial expansion, fueled by their inherent advantages in minimally invasive access and enhanced intraoperative maneuverability. Most of the robotic-assisted breast surgery has been performed using multi-arm robots. However, the implementation of single-port robotic (SPr) systems in mammary interventions continues to undergo rigorous clinical evaluation, particularly regarding long-term oncological safety and cost-effectiveness metrics.
View Article and Find Full Text PDF